A new publication dated September 26, 2026 addresses lixisenatide within a broader review of GLP-1 receptor agonist safety evaluation methods. The paper, titled "Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk," appears in the journal Regulatory Toxicology and Pharmacology.
The publication is indexed under PubMed ID 42800499. It is listed as a new entry in the scientific literature concerning regulatory frameworks used to assess carcinogenicity risk for the GLP-1RA drug class, of which lixisenatide is a member.
No findings, conclusions, or risk determinations from the paper are included in this report. This brief reflects only that the publication exists, its title, its journal, and its listed date. Readers interested in the specific content, methodology, or conclusions of the framework evaluation should consult the full text directly through the source link.
For general background on lixisenatide, including its approved regulatory status and compound overview, readers can refer to the compound overview page.